恒瑞医药(01276)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01276 恒瑞医药

未开盘 03-10 16:08:49

66.450

+1.700

+2.63%

最高67.300	最低65.600	成交量204.56万
今开65.800	昨收64.750	日振幅2.63%
总市值4,410亿	流通市值171.44亿	总股本66.37亿
成交额1.36亿	换手率0.79%	流通股本2.58亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01276","market":"HK","secType":"STK","nameCN":"恒瑞医药","latestPrice":66.45,"timestamp":1773130129002,"preClose":64.75,"halted":0,"volume":2045578,"delay":0,"changeRate":0.026254826254826297,"floatShares":258000000,"shares":6637000000,"eps":1.1387371880134574,"marketStatus":"未开盘","change":1.7,"latestTime":"03-10 16:08:49","open":65.8,"high":67.3,"low":65.6,"amount":135867322,"amplitude":0.026255,"askPrice":66.5,"askSize":1000,"bidPrice":66.45,"bidSize":200,"shortable":3,"etf":0,"ttmEps":1.3211719954307173,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1773192600000},"marketStatusCode":0,"adr":0,"listingDate":1747929600000,"exchange":"SEHK","adjPreClose":64.75,"openAndCloseTimeList":[[1773106200000,1773115200000],[1773118800000,1773129600000]],"volumeRatio":0.545653,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"600276","market":"SH","secType":"STK","nameCN":"恒瑞医药","latestPrice":56.55,"timestamp":1773126000000,"preClose":54.94,"halted":0,"volume":47360400,"delay":0,"premium":"+3.19"}},"requestUrl":"/m/hq/s/01276","defaultTab":"news","newsList":[{"id":"2618886639","title":"多家药企临床获批 / 受理，创新药行情要启动？","url":"https://stock-news.laohu8.com/highlight/detail?id=2618886639","media":"E药资本界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618886639?lang=zh_cn&edition=full","pubTime":"2026-03-10 12:01","pubTimestamp":1773115309,"startTime":"0","endTime":"0","summary":"2026 年3月以来，医药生物板块捷报频传，复星医药、科伦药业、君实生物、恒瑞医药等多家龙头及创新药企密集披露临床进展公告，覆盖新药临床试验获批、上市申请受理等关键节点。恒瑞医药 亦于近日发布公告，获得药物临床试验批准通知书，在创新药研发赛道持续深耕。随着更多新药进入临床关键阶段或获批上市，将为企业带来新的业绩增长点，同时也将推动医药生物板块向创新驱动转型。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260310121244a6b4327e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260310121244a6b4327e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0359201885.HKD","02196","06978","BK1574","01276","LU1023057109.AUD","LU0359202008.SGD","LU0359201612.USD","BK1161","LU2543165471.USD","BK1191"],"gpt_icon":0},{"id":"2618641017","title":"恒瑞医药：HRS9531注射液获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2618641017","media":"南方财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618641017?lang=zh_cn&edition=full","pubTime":"2026-03-09 17:27","pubTimestamp":1773048469,"startTime":"0","endTime":"0","summary":"南财智讯3月9日电，恒瑞医药公告，HRS9531注射液收到国家药品监督管理局签发的《药物临床试验批准通知书》，同意本品开展慢性肾脏病（CKD）的临床试验。通知书审批结论显示，该申请于2025年12月9日受理，符合药品注册有关要求。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603093666153269.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0359201885.HKD","BK1191","LU1997244956.HKD","LU2148510915.USD","LU1064131003.USD","LU1328615791.USD","LU2543165471.USD","LU1820825898.SGD","BK0060","BK0188","LU2580892789.USD","LU0359202008.SGD","LU2328871848.SGD","LU1023057109.AUD","LU2097828557.USD","BK0239","LU2289578879.USD","01276","LU1255011170.USD","LU2097828714.EUR","BK0028","LU0405327148.USD","600276","LU0359201612.USD","LU1655091616.SGD","LU1969619763.USD","LU2580892862.HKD","LU1146622755.USD","LU1580142542.USD","BK0183","LU2097828631.EUR","LU1997245094.SGD","BK0196","LU0405327494.USD","LU2097828474.EUR","LU2488822045.USD","LU1781817850.SGD","LU2495084118.USD","LU2097828805.USD","LU1997245177.USD","LU1064130708.USD","BK0012"],"gpt_icon":0},{"id":"2618104674","title":"每日卖空追踪 | 恒瑞医药 03月09日卖空量成交22.36万股，卖空比例为7.36%","url":"https://stock-news.laohu8.com/highlight/detail?id=2618104674","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618104674?lang=zh_cn&edition=full","pubTime":"2026-03-09 16:30","pubTimestamp":1773045020,"startTime":"0","endTime":"0","summary":"恒瑞医药北京时间03月09日，跌0.92%，卖空量成交22.36万股，较上一交易日减少76.18%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260309163226a6b1c5e7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260309163226a6b1c5e7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","LU1023057109.AUD","LU0359201612.USD","LU0359201885.HKD","LU0359202008.SGD","01276","LU2543165471.USD"],"gpt_icon":0},{"id":"2618118576","title":"恒瑞医药、百济神州快跑，多药企多点开花！中国创新药矩阵持续扩容","url":"https://stock-news.laohu8.com/highlight/detail?id=2618118576","media":"制药网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618118576?lang=zh_cn&edition=full","pubTime":"2026-03-09 10:27","pubTimestamp":1773023252,"startTime":"0","endTime":"0","summary":"在新药上市方面，恒瑞医药坚持差异化研发策略，以临床需求为导向，利用技术平台打造差异化创新产品矩阵，已经有20多个1类创新药获批上市。2025年上半年，公司创新药销售及许可收入95.61亿元，占公司营业收入比重60.66%。据悉，百济神州不断扩大百泽安的全球市场，持续拓展其适应症和报销覆盖，百泽安目前已在全球超过50个市场获批。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202603091102039545a61e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202603091102039545a61e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1303224171.USD","LU0359202008.SGD","BK1161","06160","BK1191","BK1500","BK1574","01276","LU0359201612.USD","06978","LU1719994722.HKD","LU2543165471.USD","LU1023057109.AUD","LU1251922891.USD","LU0307460666.USD","LU2328871848.SGD","LU1969619763.USD","LU0359201885.HKD","BK1588","BK1583","LU0588546209.SGD","LU1770034418.SGD"],"gpt_icon":0},{"id":"2618674482","title":"恒瑞医药盘中异动 早盘大幅下挫3.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=2618674482","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618674482?lang=zh_cn&edition=full","pubTime":"2026-03-09 09:51","pubTimestamp":1773021107,"startTime":"0","endTime":"0","summary":"2026年03月09日早盘09时51分，恒瑞医药股票出现波动，股价快速下挫3.06%。截至发稿，该股报63.350港元/股，成交量43.6万股，换手率0.17%，振幅3.14%。恒瑞医药股票所在的药品行业中，整体跌幅为1.19%。其相关个股中，劲方医药-B、海西新药、康臣药业涨幅较大，振幅较大的相关个股有宝济药业-B、长风药业、海西新药，振幅分别为29.68%、26.89%、13.09%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202603090951489545937b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202603090951489545937b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01276","LU1023057109.AUD","LU0359202008.SGD","LU0359201612.USD","LU0359201885.HKD","BK1191","LU2543165471.USD"],"gpt_icon":0},{"id":"2618617106","title":"国产创新药持续发力，AD治疗领域将迎来新突破","url":"https://stock-news.laohu8.com/highlight/detail?id=2618617106","media":"制药网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618617106?lang=zh_cn&edition=full","pubTime":"2026-03-09 09:29","pubTimestamp":1773019791,"startTime":"0","endTime":"0","summary":"据悉，继司普奇拜单抗之后多款国产药物也加速推进临床，并将迎来一波上市高潮。未来随着这些产品的获批上市，AD药物领域将迎来新的用药选择。随着多款新药的陆续上市，这不仅将打破国外药物垄断、降低患者用药成本，更将推动我国AD治疗的发展。未来，在政策支持与企业创新的双重驱动下，国内AD药物研发将持续突破，为全球特应性皮炎治疗贡献中国力量。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202603091000479545971d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202603091000479545971d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0348735423.USD","LU0348825331.USD","00867","LU0417516571.SGD","LU1720050803.USD","LU0348827113.USD","LU0348766576.USD","IE00B5MMRT66.SGD","02162","LU0561508036.HKD","LU0348784397.USD","IE00BPRC5H50.USD","LU2778985437.USD","LU0417516738.SGD","09926","LU0348783233.USD","01276","LU2488822045.USD","LU1961090484.USD","LU2476274308.USD","BK1161","LU2476274720.SGD","IE00B543WZ88.USD","LU2399975544.HKD","LU0417516902.SGD","LU0634319403.HKD","LU0540923850.HKD","BK1574","LU1794554557.SGD","06978","LU0348767384.USD"],"gpt_icon":0},{"id":"2618674489","title":"恒瑞医药董事长孙飘扬：以AI赋能新药研发 助力医药产业高质量发展","url":"https://stock-news.laohu8.com/highlight/detail?id=2618674489","media":"新华网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618674489?lang=zh_cn&edition=full","pubTime":"2026-03-09 08:18","pubTimestamp":1773015508,"startTime":"0","endTime":"0","summary":"2026年全国两会期间，全国人大代表、恒瑞医药董事长孙飘扬接受新华网专访，围绕AI+新药研发、医药行业数智化转型等话题，并结合行业实践与思考，为我国医药产业从“大”到“强”转型建言献策。未来，企业将持续优化科学和数据驱动的AI模型，为药物研发各环节提供自动化、智能化支持，加速创新药物开发进程。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260309081953a6b04ca0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260309081953a6b04ca0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01276","LU1023057109.AUD","LU0359202008.SGD","LU0359201612.USD","LU0359201885.HKD","BK1191","LU2543165471.USD"],"gpt_icon":0},{"id":"2617850276","title":"恒瑞医药(600276.SH)子公司阿得贝利单抗注射液获批开展临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2617850276","media":"智通财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617850276?lang=zh_cn&edition=full","pubTime":"2026-03-06 17:17","pubTimestamp":1772788650,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恒瑞医药 发布公告，近日，公司子公司上海盛迪医药有限公司收到国家药品监督管理局核准签发关于阿得贝利单抗注射液的《药物临床试验批准通知书》，将于近期开展临床试验。根据《中华人民共和国药品管理法》及有关规定，经审查，2025年12月8日受理的阿得贝利单抗注射液符合药品注册的有关要求，同意本品开展临床试验。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1411010.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["LU1997245094.SGD","LU1781817850.SGD","LU2097828557.USD","600276","LU2097828474.EUR","BK0183","01276","LU1255011170.USD","LU1997244956.HKD","LU1655091616.SGD","LU2097828805.USD","BK0028","LU1064131003.USD","LU2580892862.HKD","LU2495084118.USD","LU1820825898.SGD","LU1997245177.USD","LU1328615791.USD","BK0188","BK0196","LU2097828714.EUR","LU1064130708.USD","BK0060","BK1191","LU0359202008.SGD","LU0405327148.USD","LU1023057109.AUD","LU2148510915.USD","LU0359201885.HKD","LU2328871848.SGD","LU2580892789.USD","BK0012","LU0405327494.USD","LU2488822045.USD","LU2097828631.EUR","LU2543165471.USD","LU2289578879.USD","LU1969619763.USD","LU1580142542.USD","LU1146622755.USD","LU0359201612.USD","BK0239"],"gpt_icon":0},{"id":"2617631409","title":"【市场】24款新药确定进院，高潜力独家品种亮眼","url":"https://stock-news.laohu8.com/highlight/detail?id=2617631409","media":"米内网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617631409?lang=zh_cn&edition=full","pubTime":"2026-03-06 16:15","pubTimestamp":1772784945,"startTime":"0","endTime":"0","summary":"精彩内容日前，四川大学华西医院发布公告，决定引进24款新药，化学药及生物药均有涉及，以国谈药为主，既有尼妥珠单抗注射液等超10亿畅销品种，亦有盐酸奈康唑乳膏、依沃西单抗注射液等多个高增长的潜力品种。米内网数据显示，该药最早于2024年获批进入国内市场，2025年前三季度在中国公立医疗机构终端的销售额就突破7亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260306184223a453cbbf&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260306184223a453cbbf&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","LU0359201885.HKD","LU0359202008.SGD","LU0359201612.USD","LU2543165471.USD","LU1023057109.AUD","01276"],"gpt_icon":0},{"id":"2617631406","title":"恒瑞医药03月06日获主力加仓255.2万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2617631406","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617631406?lang=zh_cn&edition=full","pubTime":"2026-03-06 16:15","pubTimestamp":1772784907,"startTime":"0","endTime":"0","summary":"03月06日, 恒瑞医药股价涨4.81%，报收65.35元，成交金额2.3亿元，换手率1.36%，振幅5.61%，量比0.95。恒瑞医药今日主力资金净流入255.2万元，连续4日净流入，上一交易日主力净流入3696.4万元。近一年数据显示，该股主力连续4日净流入后，次日上涨概率为42.86%，平均涨幅为1.26%。该股近5个交易日下跌2.56%，主力资金累计净流入5128.2万元；近20日主力资金累计净流入9559.3万元，其中净流入天数为14日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260306161516a6aa28d0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260306161516a6aa28d0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","LU0359201612.USD","LU1023057109.AUD","LU0359202008.SGD","LU2543165471.USD","LU0359201885.HKD","01276"],"gpt_icon":0},{"id":"2617403631","title":"恒瑞入局，明瑞能否守住阵地？","url":"https://stock-news.laohu8.com/highlight/detail?id=2617403631","media":"药智数据","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617403631?lang=zh_cn&edition=full","pubTime":"2026-03-06 14:23","pubTimestamp":1772778186,"startTime":"0","endTime":"0","summary":"同期，94个品种申报一致性评价。01成都恒瑞：马尿酸乌洛托品片3月2日，CDE发布公示，成都恒瑞制药马尿酸乌洛托品片上市申请正式获得受理，这是继湖南明瑞制药之后，国内第二家递交该品种上市申请的企业，意味着这一细分市场即将迎来新的竞争者。此次成都恒瑞报产获受理，释放出的信号很明确，一些竞争温和、已有临床基础的老品种，仍在吸引药企重新布局。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260306150733a6a9e37a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260306150733a6a9e37a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01276","BK1191","LU0359201612.USD","LU1023057109.AUD","LU2543165471.USD","LU0359202008.SGD","LU0359201885.HKD"],"gpt_icon":0},{"id":"2617477631","title":"瞩目，恒瑞医药1新新药又一研究成果荣登顶级医学期刊","url":"https://stock-news.laohu8.com/highlight/detail?id=2617477631","media":"北京药研汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617477631?lang=zh_cn&edition=full","pubTime":"2026-03-06 12:00","pubTimestamp":1772769657,"startTime":"0","endTime":"0","summary":"鼻咽癌，这一具有显著地域差异性的恶性肿瘤，其全球发病状况呈现出不均衡性。2026年3月5日，恒瑞医药官方发布，近日，其创新药卡瑞利珠单抗一项高危局晚期鼻咽癌Ⅲ期临床研究成果重磅发表于国际顶级医学期刊《英国医学杂志》。综上，卡瑞利珠单抗在复发/转移性鼻咽癌及局晚期鼻咽癌患者研究中均展现出治疗获益，且安全性可控。其相关研究此前多次刊登于《柳叶刀》《美国医学会杂志》等国际顶级学术期刊。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260306124500a4529569&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260306124500a4529569&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2543165471.USD","LU0359201612.USD","BK1191","01276","LU0359202008.SGD","LU0359201885.HKD","LU1023057109.AUD"],"gpt_icon":0},{"id":"2617066845","title":"创新药板块强势 三生制药(01530)涨9.83% 机构指业绩兑现有望催化板块行情","url":"https://stock-news.laohu8.com/highlight/detail?id=2617066845","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617066845?lang=zh_cn&edition=full","pubTime":"2026-03-06 10:41","pubTimestamp":1772764875,"startTime":"0","endTime":"0","summary":"金吾财讯 | 创新药板块强势，三生制药 涨9.83%，基石药业-B涨6.84%，荣昌生物涨6.31%，映恩生物-B涨5.98%，四环医药涨5.76%，恒瑞医药涨5.77%，君圣泰医药-B涨5.58%，康诺亚-B涨5.31%，复宏汉霖涨5.02%。交银国际表示，本周各公司业绩预告陆续发布，该机构建议持续关注财务表现超预期、盈利路径清晰的公司，其业绩兑现有望催化板块行情。","market":"fut","thumbnail":"https://static.szfiu.com/news/20241108/MGQ5MWNhYjgxMjA0ZDU3OGI4Y2EzYTk1OWIyNGM1NTg2NTUyNjEzMTk5Ng==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/MGQ5MWNhYjgxMjA0ZDU3OGI4Y2EzYTk1OWIyNGM1NTg2NTUyNjEzMTk5Ng==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1976042","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0359201612.USD","HK0000306685.HKD","LU0359202008.SGD","HK0000320223.HKD","09606","01276","LU1023057109.AUD","BK1593","01530","HK0000165453.HKD","HK0000252160.HKD","BK1515","06978","159992","LU0359201885.HKD","02511","BK1191","BK1161","02162","HK0000306701.USD","BK1600","BK1574","HK0000252152.HKD","09995","LU2543165471.USD","LU2328871848.SGD","BK1583","HK0000500386.USD","02616","HK0000320264.USD","02696","LU1969619763.USD","BK1587","00460"],"gpt_icon":0},{"id":"2617572723","title":"恒瑞创新药卡瑞利珠单抗显著提升高危鼻咽癌患者生存率，研究成果登顶国际顶刊","url":"https://stock-news.laohu8.com/highlight/detail?id=2617572723","media":"市场资讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617572723?lang=zh_cn&edition=full","pubTime":"2026-03-05 19:34","pubTimestamp":1772710474,"startTime":"0","endTime":"0","summary":"据恒瑞医药消息，近日，恒瑞医药创新药卡瑞利珠单抗一项针对高危局晚期鼻咽癌的III期临床研究结果，在国际顶级医学期刊《英国医学杂志》正式发表。该研究证实，在标准同步放化疗基础上联用卡瑞利珠单抗并序贯辅助治疗，可显著改善高危局晚期鼻咽癌患者的无进展生存期，为这类高复发风险患者带来了新的治疗希望。本研究旨在探索卡瑞利珠单抗用于高危局晚期鼻咽癌患者的最佳治疗策略。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260305195720a6a69cec&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260305195720a6a69cec&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","LU0359201612.USD","LU0359201885.HKD","LU1023057109.AUD","LU2543165471.USD","06978","BK1161","BK1191","01276","LU0359202008.SGD"],"gpt_icon":0},{"id":"2617721572","title":"每日卖空追踪 | 恒瑞医药 03月05日卖空量成交39.18万股，卖空比例为7.49%","url":"https://stock-news.laohu8.com/highlight/detail?id=2617721572","media":"市场透视","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617721572?lang=zh_cn&edition=full","pubTime":"2026-03-05 16:30","pubTimestamp":1772699421,"startTime":"0","endTime":"0","summary":"恒瑞医药北京时间03月05日，涨3.57%，卖空量成交39.18万股，较上一交易日增加39.63%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260305163223a44ef622&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260305163223a44ef622&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0359201612.USD","LU2543165471.USD","LU0359202008.SGD","BK1191","LU1023057109.AUD","LU0359201885.HKD","01276"],"gpt_icon":0},{"id":"2617457272","title":"从恒瑞、协和麒麟看医药创新的残酷AB面","url":"https://stock-news.laohu8.com/highlight/detail?id=2617457272","media":"药视声Medispace","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617457272?lang=zh_cn&edition=full","pubTime":"2026-03-05 13:06","pubTimestamp":1772687176,"startTime":"0","endTime":"0","summary":"一边，恒瑞医药以一份“零意外”的董事会名单，上演了“全家福”般的稳定剧情。另一边，日本协和麒麟宣布全面终止rocatinlimab的所有临床试验。直接原因是临床试验中出现新增的确诊及疑似卡波西肉瘤病例，引发严重安全忧虑。医药创新的AB面医药行业的创新，由两种底色绘就：恒瑞的“稳”与协和麒麟的“险”。协和麒麟的折戟，揭示了原创新药研发“九死一生”的法则。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260305133507a44e4de0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260305133507a44e4de0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","01276","LU1023057109.AUD","BK1574","LU2543165471.USD","BK1515","BK1191","LU0359201885.HKD","LU0359202008.SGD","09939","LU0359201612.USD"],"gpt_icon":0},{"id":"2617559182","title":"港股恒瑞医药涨超6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2617559182","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617559182?lang=zh_cn&edition=full","pubTime":"2026-03-05 10:58","pubTimestamp":1772679537,"startTime":"0","endTime":"0","summary":"每经AI快讯，恒瑞医药(01276.HK)涨超6%，截至发稿，涨6.15%，报63.9港元，成交额1.13亿港元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202603053662905861.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603053662905861.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1997245094.SGD","LU1781817850.SGD","LU2097828557.USD","600276","LU2097828474.EUR","BK0183","01276","LU1255011170.USD","LU1997244956.HKD","BK4585","LU1655091616.SGD","LU2097828805.USD","BK0028","LU1064131003.USD","LU2580892862.HKD","LU2495084118.USD","LU1820825898.SGD","LU1997245177.USD","LU1328615791.USD","BK0188","VT","BK0196","LU2097828714.EUR","LU1064130708.USD","BK0060","BK1191","LU0359202008.SGD","LU0405327148.USD","LU1023057109.AUD","LU2148510915.USD","LU0359201885.HKD","LU2328871848.SGD","LU2580892789.USD","BK0012","LU0405327494.USD","LU2488822045.USD","LU2097828631.EUR","LU2543165471.USD","LU2289578879.USD","LU1969619763.USD","VXUS","LU1580142542.USD","LU1146622755.USD","LU0359201612.USD","BK0239","BK4588"],"gpt_icon":0},{"id":"2616538025","title":"恒瑞医药(01276)子公司药品HRS-1780片获得药物临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2616538025","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616538025?lang=zh_cn&edition=full","pubTime":"2026-03-04 17:05","pubTimestamp":1772615158,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恒瑞医药(01276)发布公告，近日，江苏恒瑞医药股份有限公司(以下简称“公司”)子公司山东盛迪医药有限公司收到国家药品监督管理局(以下简称“国家药监局”)核准签发关于HRS-1780片的《药物临床试验批准通知书》，将于近期开展临床试验。HRS-1780 片是盐皮质激素受体拮抗剂，临床拟用于治疗原发性醛固酮增多症。原发性醛固酮增多症的一线治疗药物为盐皮质激素受体拮抗剂，目前仅螺内酯获批，但螺内酯有性激素相关副作用。截至目前，HRS-1780片相关项目累计研发投入约为7040万元(未经审计)。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1409964.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0405327494.USD","BK0028","LU1655091616.SGD","BK0060","LU1255011170.USD","LU2097828474.EUR","LU1997245094.SGD","LU1997245177.USD","LU2495084118.USD","BK0239","LU2097828714.EUR","BK0196","LU1997244956.HKD","LU2328871848.SGD","BK1191","LU1580142542.USD","LU2148510915.USD","LU1781817850.SGD","LU2097828805.USD","LU1023057109.AUD","LU1328615791.USD","01276","LU1064131003.USD","LU2580892789.USD","LU1064130708.USD","BK0188","LU0359202008.SGD","LU0359201885.HKD","LU0359201612.USD","LU0405327148.USD","LU1820825898.SGD","LU1969619763.USD","LU2543165471.USD","600276","BK0012","LU2488822045.USD","LU1146622755.USD","LU2289578879.USD","LU2097828557.USD","BK0183","LU2097828631.EUR","LU2580892862.HKD"],"gpt_icon":0},{"id":"1178296534","title":"江苏恒瑞医药(600276)回购63万股A股，总额约3,398.21万元","url":"https://stock-news.laohu8.com/highlight/detail?id=1178296534","media":"公告速递","labels":["shareholding","buyback","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1178296534?lang=zh_cn&edition=full","pubTime":"2026-03-03 17:07","pubTimestamp":1772528852,"startTime":"0","endTime":"0","summary":"江苏恒瑞医药股份有限公司(600276)于2026年3月3日发布翌日披露报表，宣布回购A股63万股，占回购前公司已发行股本约0.0099%。此次回购价格区间为每股人民币53.52元至54.27元，合计支付约3,398.21万元。\n回购完成后，公司已发行股份(不包括库藏股)数量变动为6,372,214,624股，库藏股数量增至6,787,650股。公司在公告中确认，本次回购已获得董事会正式授权，并遵守所有适用的上市规则和相关法律法规。\n本次公告由联席公司秘书刘笑含签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01276"],"gpt_icon":0},{"id":"2616609310","title":"恒瑞医药(01276)3月3日斥资3398.21万元回购63万股A股","url":"https://stock-news.laohu8.com/highlight/detail?id=2616609310","media":"智通财经","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616609310?lang=zh_cn&edition=full","pubTime":"2026-03-03 17:05","pubTimestamp":1772528735,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恒瑞医药(01276)发布公告，于2026年3月3日斥资人民币3398.21万元回购63万股A股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1409478.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2097828805.USD","LU0359201885.HKD","LU1580142542.USD","LU1820825898.SGD","LU2488822045.USD","LU1023057109.AUD","LU1969619763.USD","LU1997244956.HKD","LU2097828557.USD","LU1781817850.SGD","LU1255011170.USD","01276","BK0060","BK0188","LU1655091616.SGD","159982","LU2148510915.USD","LU0405327494.USD","BK0239","BK0028","LU2097828714.EUR","LU2580892789.USD","LU2097828474.EUR","LU2328871848.SGD","LU1064130708.USD","BK0183","LU2289578879.USD","LU2543165471.USD","LU2097828631.EUR","LU1328615791.USD","BK1191","BK0196","LU1997245177.USD","BK0012","LU1064131003.USD","LU0359201612.USD","LU2580892862.HKD","399300","600276","LU2495084118.USD","LU1146622755.USD","LU0405327148.USD","LU1997245094.SGD","LU0359202008.SGD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.hrs.com.cn","stockEarnings":[{"period":"1week","weight":0.0632},{"period":"1month","weight":-0.0177},{"period":"3month","weight":-0.1158},{"period":"6month","weight":-0.2004},{"period":"1year","weight":0.5085},{"period":"ytd","weight":-0.0674}],"compareEarnings":[{"period":"1week","weight":0.0074},{"period":"1month","weight":-0.0226},{"period":"3month","weight":0.0164},{"period":"6month","weight":-0.0048},{"period":"1year","weight":0.0915},{"period":"ytd","weight":0.0129}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"江苏恒瑞医药股份有限公司是一家主要从事药品的研发、生产和销售的中国公司。该公司专注于肿瘤领域，覆盖激酶抑制剂、抗体偶联药物（ADC）、肿瘤免疫、激素受体调控、脱氧核糖核酸（DNA）修复及表观遗传、支持治疗等研究领域。该公司的产品包括抗肿瘤、镇痛麻醉和造影剂，应用于自身免疫疾病、代谢性疾病、心血管疾病、感染疾病、呼吸系统疾病、血液疾病、疼痛管理、神经系统疾病、眼科、肾病等领域。该公司主要在国内外市场开展其业务。","exchange":"SEHK","name":"恒瑞医药","nameEN":"HENGRUI PHARMA"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"恒瑞医药(01276)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供恒瑞医药(01276)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"恒瑞医药,01276,恒瑞医药股票,恒瑞医药股票老虎,恒瑞医药股票老虎国际,恒瑞医药行情,恒瑞医药股票行情,恒瑞医药股价,恒瑞医药股市,恒瑞医药股票价格,恒瑞医药股票交易,恒瑞医药股票购买,恒瑞医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"恒瑞医药(01276)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供恒瑞医药(01276)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}